Facharzt FMH Medizinische Onkologie Practice Questions - Facharzt FMH Für Medizinische Onkologie Spécialiste FMH En Oncologie Médicale Exam

Access More Questions

A 38-year-old woman with a documented deleterious germline BRCA1 mutation completes neoadjuvant anthracycline/taxane chemotherapy and bilateral mastectomy for triple-negative breast cancer. Final surgical pathology reveals residual invasive carcinoma measuring 1.8 cm with 1 positive axillary lymph node (ypT1c ypN1a, non-pCR). Which adjuvant targeted therapy is indicated based on the Phase III OlympiA trial to improve invasive disease-free and overall survival?

Adjuvant Olaparib orally for 1 year Adjuvant Talazoparib orally for 6 months Adjuvant Niraparib combined with bevacizumab for 2 years Adjuvant Rucaparib monotherapy for 3 years

Correct Answer:

Adjuvant Olaparib orally for 1 year

Access more questions from this quiz

Continue to Facharzt FMH Medizinische Onkologie Practice Questions - Facharzt FMH für Medizinische Onkologie Spécialiste FMH en oncologie médicale Exam for more practice questions and the full quiz experience.

Access More Questions